Producers of veterinary innovations can help minimize decision fatigue
By Shauna Glynn, DVM
The pace of innovation in animal health has accelerated dramatically in recent years. New animal drugs are reaching the market at an unprecedented rate—introducing treatments for disease states that once had few or no options, as well as novel approaches to managing familiar conditions. This progress is reshaping what is clinically possible in veterinary medicine as well as the day‑to‑day reality of veterinary decision‑making.
And it raises an important question: How can the companies producing these innovations help reduce decision fatigue for veterinarians?
On one hand, expanded therapeutic options offer veterinarians greater ability to tailor care, improve outcomes, and practice medicine at a higher level. On the other, each new drug adds complexity: another mechanism of action to understand, another risk/benefit profile to evaluate, another cost consideration to communicate to pet owners. Keeping pace requires continuous learning and precise clinical judgment, often under significant time pressure.
This growing cognitive burden is not occurring in a vacuum. The 2026 Merck Animal Health Wellbeing Study found that veterinarians experience nearly 40% higher burnout than human physicians, with cognitive depletion (often driven by the constant navigation of complex medical and financial decisions) identified as a key contributing factor. As innovation accelerates, so does decision fatigue.
As innovation accelerates, the role of animal pharmaceutical companies extends beyond education toward enabling confident, efficient decision‑making. Veterinarians are not lacking information; they are navigating too much of it. The opportunity for industry lies in reducing complexity at the moment care decisions are made.
Education is most effective when it functions as practical decision support. While understanding drug class, mechanism of action, dosing, and safety is essential, veterinary teams also need help contextualizing where new therapies fit within existing treatment options. Clear comparisons, appropriate-use guidance, and real‑world application help veterinarians make informed choices without adding friction to an already demanding workflow.
This support must continue well beyond product launch. Ongoing access to streamlined, easy‑to‑navigate resources – including updated safety data, expert insights, and real‑world learnings – allows veterinarians to revisit information as questions arise. When knowledge is accessible over time, it supports confidence rather than contributing to cognitive overload.
Adverse event concerns further complicate adoption of new therapies. Many veterinarians hesitate to use newly approved products until they have a longer post‑market track record, reflecting rational caution around unknown risks. Here, trust is critical. Transparent communication about the approval process, proactive sharing of post‑market insights, and clear guidance for managing unexpected outcomes can help veterinarians assess new therapies with greater confidence.
Equally important is support when adverse events do occur. Managing a clinical complication while guiding a concerned pet owner adds emotional strain to an already stressful situation. Prompt access to technical services, clear contact pathways, and visibility into real‑world adverse event data can provide meaningful relief and reinforce a sense of partnership.
Veterinarians do not need to be challenged to think critically – they already do so every day. What has changed is the weight of each decision as the therapeutic landscape grows more complex. By prioritizing practical decision support, transparency, and accessible human engagement, animal health companies can help reduce decision fatigue while strengthening trust, improving outcomes, and supporting the wellbeing of the professionals delivering care.